Menée à partir de données portant sur 201 patients présentant des métastases hépatiques bilobaires ayant pour origine un cancer colorectal (âge : 50 à 71 ans), cette étude multicentrique évalue, du point de vue de la survie et des complications, l'intérêt d'ajouter une hépatectomie à une ablation par micro-ondes

Single-stage resection and microwave ablation for bilobar colorectal liver metastases

Philips, P. ; Groeschl, R. T. ; Hanna, E. M. ; Swan, R. Z. ; Turaga, K. K. ; Martinie, J. B. ; Iannitti, D. A. ; Schmidt, C. ; Clark Gamblin, T. ; Martin, R. C. G.

Background : Patients undergoing liver resection combined with microwave ablation (MWA) for bilobar colorectal metastasis may have similar overall survival to patients who undergo two-stage hepatectomy, but with less morbidity. Methods : This was a multi-institutional evaluation of patients who underwent MWA between 2003 and 2012. Morbidity (90-day) and mortality were compared between patients who had MWA alone and those who underwent combined resection and MWA (CRA). Mortality and overall [...]

Menée auprès de 81 patients atteints d'un cancer de la prostate ayant récidivé avec une extension ganglionnaire, cette étude analyse les toxicités et l'efficacité, sur la survie sans progression et la survie globale à 3 ans, d'une radiothérapie hélicoïdale de sauvetage guidée par l'image (durée médiane de suivi : 36 mois)

Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer

Fodor, Andrei ; Berardi, Genoveffa ; Fiorino, Claudio ; Picchio, Maria ; Busnardo, Elena ; Kirienko, Margarita ; Incerti, Elena ; Dell'Oca, Italo ; Cozzarini, Cesare ; Mangili, Paola ; Pasetti, Marcella ; Calandrino, Riccardo ; Gianolli, Luigi ; Di Muzio, Nadia G.

Objective : To report the 3-year toxicity and outcomes of carbon 11 (11C)-choline-positron emission tomography (PET)/computed tomography (CT)-guided radiotherapy (RT), delivered via helical tomotherapy (HTT; Tomotherapy® Hi-Art II® Treatment System, Accuray Inc., Sunnyvale, CA, USA) after lymph node (LN) relapses in patients with prostate cancer. Patients and Methods : From January 2005 to March 2013, 81 patients with biochemical recurrence after surgery, with or without adjuvant/salvage RT or [...]

A partir d'une revue de la littérature publiée jusqu'en novembre 2015 (9 essais), cette méta-analyse met en évidence, par rapport à une radiothérapie du sein entier et du point de vue de la mortalité à 5 ans, l'intérêt d'une irradiation mammaire partielle chez les patientes atteintes d'un cancer du sein de stade précoce (8 720 cas)

Reduced mortality with partial breast irradiation for early breast cancer – a meta-analysis of randomised trials

Vaidya, Jayant S. ; Bulsara, Max ; Wenz, Frederik ; Coombs, Nathan ; Singer, Julian ; Ebbs, Stephen ; Massarut, Samuele ; Saunders, Christobel ; Douek, Michael ; Williams, Norman ; Joseph, David ; Tobias, Jeffrey S. ; Baum, Michael

Background : With earlier detection and more effective treatment, mortality from breast cancer continues to fall and it has become increasingly important to reduce the toxicity of treatments. Partial breast radiotherapy, which focuses radiation to the tumour bed may achieve this aim. We analysed mortality differences in randomised trials of partial breast irradiation. Method : We included data from published randomized trials of partial breast irradiation (alone or as part of a risk-adapted [...]

Cet article passe en revue les perspectives offertes par la combinaison de thérapies ciblées et d'immunothérapies (anti PD1/PD-L1 et anti CTLA-4) pour le traitement des patients atteints d'un cancer

Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer

Hughes, Paul E. ; Caenepeel, Sean ; Wu, Lawren C.

Many advances in the treatment of cancer have been driven by the development of targeted therapies that inhibit oncogenic signaling pathways and tumor-associated angiogenesis, as well as by the recent development of therapies that activate a patient's immune system to unleash antitumor immunity. Some targeted therapies can have effects on host immune responses, in addition to their effects on tumor biology. These immune-modulating effects, such as increasing tumor antigenicity or promoting [...]

Menée sur des lignées cellulaires, cette étude met en évidence l'activité antitumorale d'une nouvelle classe d'inhibiteurs de mTOR susceptibles de surmonter une résistance thérapeutique aux première et deuxième générations d'inhibiteurs de mTOR

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor

Rodrik-Outmezguine, Vanessa S. ; Okaniwa, Masanori ; Yao, Zhan ; Novotny, Chris J. ; McWhirter, Claire ; Banaji, Arpitha ; Won, Helen ; Wong, Wai ; Berger, Mike ; de Stanchina, Elisa ; Barratt, Derek G. ; Cosulich, Sabina ; Klinowska, Teresa ; Rosen, Neal ; Shokat, Kevan M.

Precision medicines exert selective pressure on tumour cells that leads to the preferential growth of resistant subpopulations, necessitating the development of next-generation therapies to treat the evolving cancer. The PIK3CA–AKT–mTOR pathway is one of the most commonly activated pathways in human cancers, which has led to the development of small-molecule inhibitors that target various nodes in the pathway. Among these agents, first-generation mTOR inhibitors (rapalogs) have caused responses [...]

Menée sur des lignées cellulaires de leucémie lymphoblastique aiguë réfractaire/récidivante et à l'aide de xénogreffes sur des modèles murins, cette étude met en évidence des mécanismes suggérant l'intérêt d'un traitement combinant un mimétique de SMAC (birinapant) et un inhibiteur de caspase

Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL

McComb, Scott ; Aguadé-Gorgorió, Júlia ; Harder, Lena ; Marovca, Blerim ; Cario, Gunnar ; Eckert, Cornelia ; Schrappe, Martin ; Stanulla, Martin ; von Stackelberg, Arend ; Bourquin, Jean-Pierre ; Bornhauser, Beat C.

Second mitochondria-derived activator of caspases, or SMAC, is a protein involved in apoptosis, a mechanism of cell death that is commonly targeted by cancer therapies. SMAC mimetics are drugs designed to mimic the action of SMAC. Now, a pair of related articles provides insights into the effects of SMAC mimetics in leukemia. For acute lymphocytic leukemia, McComb et al. show that a SMAC mimetic called birinapant works best when it can activate two different types of cell death: apoptosis and [...]

Cet article passe en revue les perspectives thérapeutiques offertes par les travaux récents sur la biologie des cancers du sein triplement négatif

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

Bianchini, Giampaolo ; Balko, Justin M. ; Mayer, Ingrid A. ; Sanders, Melinda E. ; Gianni, Luca

Chemotherapy is the primary established systemic treatment for patients with triple-negative breast cancer (TNBC) in both the early and advanced-stages of the disease. The lack of targeted therapies and the poor prognosis of patients with TNBC have fostered a major effort to discover actionable molecular targets to treat patients with these tumours. Massively parallel sequencing and other 'omics' technologies have revealed an unexpected level of heterogeneity of TNBCs and have led to the [...]

Menée à l'aide de modèles murins de glioblastome multiforme, cette étude met en évidence des mécanismes liés au micro-environnement tumoral permettant de rendre compte de l'apparition d'une résistance à un traitement à base d'anticorps anti CSF-1R

The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas

Quail, Daniela F. ; Bowman, Robert L. ; Akkari, Leila ; Quick, Marsha L. ; Schuhmacher, Alberto J. ; Huse, Jason T. ; Holland, Eric C. ; Sutton, James C. ; Joyce, Johanna A.

INTRODUCTION : Therapies targeted against the tumor microenvironment (TME) represent a promising approach for treating cancer. This appeal arises in part from the decreased likelihood of acquired resistance through mutations in target TME cells, as is frequently observed with cancer cell–targeted therapies. Although classical mechanisms of tumor cell–intrinsic resistance to cytotoxic and targeted agents have been well-defined—including aberrant drug metabolism and transport, drug target [...]

Menée in vitro et in vivo sur des modèles de cancer de la thyroïde, cette étude met en évidence des mécanismes par lesquels l'activation de la voie de signalisation MAPK favorise la résistance au dasatinib

The Mitogen Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor, Dasatinib, in Thyroid Cancer

Beadnell, Thomas C ; Mishall, Katie M ; Zhou, Qiong ; Riffert, Stephen M ; Wuensch, Kelsey E ; Kessler, Brittelle E. ; Corpuz, Maia L ; Jing, Xia ; Kim, Jihye ; Wang, Guoliang ; Tan, Aik Choon ; Schweppe, Rebecca E.

Advanced stages of papillary and anaplastic thyroid cancer represent a highly aggressive subset, in which there are currently few effective therapies. We and others have recently demonstrated that c-Src is a key mediator of growth, invasion, and metastasis, and therefore represents a promising therapeutic target in thyroid cancer. However clinically, Src inhibitor efficacy has been limited, and therefore further insights are needed to define resistance mechanisms and determine rational [...]

Mené sur 225 patients atteints d'une tumeur solide de stade avancé (sein, glioblastome, mélanome, côlon-rectum, poumon non à petites cellules), cet essai de phase I évalue la dose maximale tolérée et l'activité antitumorale de l'abemaciclib, un inhibiteur de CDK4 et CDK6

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

Patnaik, Amita ; Rosen, Lee S. ; Tolaney, Sara M. ; Tolcher, Anthony W. ; Goldman, Jonathan W. ; Gandhi, Leena ; Papadopoulos, Kyriakos P. ; Beeram, Muralidhar ; Rasco, Drew W. ; Hilton, John F. ; Nasir, Aejaz ; Beckmann, Richard P. ; Schade, Andrew E. ; Fulford, Angie D. ; Nguyen, Tuan S. ; Martinez, Ricardo ; Kulanthaivel, Palaniappan ; Li, Lily Q. ; Frenzel, Martin ; Cronier, Damien M. ; Chan, Edward M. ; Flaherty, Keith T. ; Wen, Patrick Y. ; Shapiro, Geoffrey I.

We evaluated the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of abemaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDK) 4 and 6, in a multicenter study including phase I dose escalation followed by tumor-specific cohorts for breast cancer, non–small cell lung cancer (NSCLC), glioblastoma, melanoma, and colorectal cancer. A total of 225 patients were enrolled: 33 in dose escalation and 192 in tumor-specific cohorts. Dose-limiting [...]

Mené sur 519 patients atteints d'une leucémie myéloïde chronique, cet essai randomisé international compare l'efficacité, du point de vue de la survie sans progression et de la survie globale, du dasatinib et de l'imatinib en première ligne (durée de suivi : 5 ans)

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

Cortes, Jorge E. ; Saglio, Giuseppe ; Kantarjian, Hagop M. ; Baccarani, Michele ; Mayer, Jiri ; Boqué, Concepción ; Shah, Neil P. ; Chuah, Charles ; Casanova, Luis ; Bradley-Garelik, Brigid ; Manos, George ; Hochhaus, Andreas

Purpose We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term efficacy and safety outcomes of patients with chronic myeloid leukemia (CML) in chronic phase (CP) treated with dasatinib or imatinib. Patients and Methods Patients with newly diagnosed CML-CP were randomly assigned to receive dasatinib 100 mg once daily (n = 259) or imatinib 400 mg once daily (n = 260). Results At [...]

Mené sur 758 patients atteints d'un lymphome diffus à grandes cellules B en rémission complète et à haut risque de récidive après un traitement de première ligne, cet essai randomisé international de phase III évalue l'efficacité, du point de vue de la survie sans maladie, et la toxicité de l'enzastaurine (durée médiane de suivi : 48 mois)

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma

Crump, Michael ; Leppä, Sirpa ; Fayad, Luis ; Lee, Je Jung ; Di Rocco, Alice ; Ogura, Michinori ; Hagberg, Hans ; Schnell, Frederick ; Rifkin, Robert ; Mackensen, Andreas ; Offner, Fritz ; Pinter-Brown, Lauren ; Smith, Sonali ; Tobinai, Kensei ; Yeh, Su-Peng ; Hsi, Eric D. ; Nguyen, Tuan ; Shi, Peipei ; Hahka-Kemppinen, Marjo ; Thornton, Don ; Lin, Boris ; Kahl, Brad ; Schmitz, Norbert ; Savage, Kerry J. ; Habermann, Thomas

Purpose To compare disease-free survival (DFS) after maintenance therapy with the selective protein kinase C β (PKCβ) inhibitor, enzastaurin, versus placebo in patients with diffuse large B-cell lymphoma (DLBCL) in complete remission and with a high risk of relapse after first-line therapy. Patients and Methods This multicenter, phase III, randomized, double-blind, placebo-controlled trial enrolled patients who were at high risk of recurrence after rituximab-cyclophosphamide, doxorubicin, [...]

Mené sur 101 patients atteints d'un mélanome métastatique, cet essai randomisé évalue l'efficacité, du point de vue du taux de réponse complète et de la survie globale, d'une irradiation corporelle totale avant un transfert adoptif de lymphocytes infiltrant les tumeurs

Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Goff, Stephanie L. ; Dudley, Mark E. ; Citrin, Deborah E. ; Somerville, Robert P. ; Wunderlich, John R. ; Danforth, David N. ; Zlott, Daniel A. ; Yang, James C. ; Sherry, Richard M. ; Kammula, Udai S. ; Klebanoff, Christopher A. ; Hughes, Marybeth S. ; Restifo, Nicholas P. ; Langhan, Michelle M. ; Shelton, Thomas E. ; Lu, Lily ; Kwong, Mei Li M. ; Ilyas, Sadia ; Klemen, Nicholas D. ; Payabyab, Eden C. ; Morton, Kathleen E. ; Toomey, Mary Ann ; Steinberg, Seth M. ; White, Donald E. ; Rosenberg, Steven A.

Purpose Adoptive cell transfer, the infusion of large numbers of activated autologous lymphocytes, can mediate objective tumor regression in a majority of patients with metastatic melanoma (52 of 93; 56%). Addition and intensification of total body irradiation (TBI) to the preparative lymphodepleting chemotherapy regimen in sequential trials improved objective partial and complete response (CR) rates. Here, we evaluated the importance of adding TBI to the adoptive transfer of tumor-infiltrating [...]

Mené sur 107 patientes atteintes d'un carcinome récidivant du péritoine, d'une trompe de Fallope ou d'un ovaire, cet essai randomisé de phase II évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité d'un traitement combinant deux agents anti-angiogéniques (bévacizumab et trométhamine fosbretabuline)

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

Monk, Bradley J. ; Sill, Michael W. ; Walker, Joan L. ; Darus, Christopher J. ; Sutton, Gregory ; Tewari, Krishnansu S. ; Martin, Lainie P. ; Schilder, Jeanne M. ; Coleman, Robert L. ; Balkissoon, Jai ; Aghajanian, Carol

Purpose The vascular disrupting agent fosbretabulin tromethamine selectively targets pre-existing tumor vasculature, which causes vascular shutdown and leads to cancer cell death and necrosis. Antiangiogenesis agents such as bevacizumab, a humanized antivascular endothelial growth factor monoclonal antibody, might prevent revascularization during and after treatment with a vascular disrupting agent. Patients and Methods Patients with recurrent or persistent epithelial ovarian, tubal, or [...]

Cet article passe en revue les travaux récents sur le traitement des patients atteints d'un cancer du poumon EGFR+ ayant développé une résistance à un inhibiteur d'EGFR (erlotinib, gefinitib, afatinib)

Treatment of EGFR-mutant lung cancers after progression in patients receiving first-line EGFR tyrosine kinase inhibitors : A review

Piotrowska, Z. ; Sequist, L. V.

Importance  Patients with EGFR-mutant lung cancer benefit from treatment with EGFR inhibitors such as erlotinib, gefitinib, and afatinib, but outcomes are limited by the eventual development of resistance to these agents. Over half of patients acquire a secondary T790M mutation in EGFR at the time of progression and a substantial minority develops resistance through other mechanisms. Multiple treatment strategies are now available to patients whose disease has progressed on their initial EGFR [...]

Cet article présente les recommandations de l'"American Society of Clinical Oncology" en matière d'hormonothérapies pour les patientes atteintes d'un cancer métastatique du sein HR+

Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

Rugo, Hope S. ; Rumble, R. Bryan ; Macrae, Erin ; Barton, Debra L. ; Connolly, Hannah Klein ; Dickler, Maura N. ; Fallowfield, Lesley ; Fowble, Barbara ; Ingle, James N. ; Jahanzeb, Mohammad ; Johnston, Stephen R.D. ; Korde, Larissa A. ; Khatcheressian, James L. ; Mehta, Rita S. ; Muss, Hyman B. ; Burstein, Harold J.

Purpose To develop recommendations about endocrine therapy for women with hormone receptor (HR) –positive metastatic breast cancer (MBC). Methods The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of evidence from 2008 through 2015 to create recommendations informed by that evidence. Outcomes of interest included sequencing of hormonal agents, hormonal agents compared with chemotherapy, targeted biologic therapy, and treatment of premenopausal [...]

Cette étude passe en revue les études concernant l'intérêt, du point de vue du contrôle de la maladie, de la survie ou de la toxicité, d'une radiothérapie hypofractionnée standard et d'une radiothérapie corporelle stéréotaxique dans le traitement d'un cancer du pancréas

Hypofractionated radiotherapy in pancreatic cancer : Lessons from the past in the era of stereotactic body radiation therapy

Berardino, De Bari ; Laetitia, Porta ; Rosario, Mazzola ; Filippo, Alongi ; Wagner, Anna Dorothea ; Markus, Schäfer ; Jean, Bourhis ; Mahmut, Ozsahin

The role of neoadjuvant and definitive radiotherapy combined or not to chemotherapy in the therapeutic approach to pancreatic cancer has not been yet elucidated. There is some evidence in favour of neoadjuvant local and/or systemic approaches that enable surgical resection in patients initially considered to be “borderline resectable”. Nevertheless, most of these studies have been conducted using schedules of radiotherapy (treatment volumes, total doses, dose/fraction) that are nowadays [...]

Mené en Corée du Sud sur 22 patients atteints d'un cancer rectal de stade cT3-4N0 ou cTanyN1-2, cet essai de phase I évalue la dose limitante toxique du témolozomide en combinaison avec une chimioradiothérapie pré-opératoire à base de capécitabine

Phase I Study of Preoperative Chemoradiation with Temozolomide and Capecitabine in Patients with Locally Advanced Rectal Cancer

Jeong, Jae Ho ; Hong, Yong Sang ; Park, Yangsoon ; Kim, Jihun ; Kim, Jeong Eun ; Kim, Kyu-pyo ; Kim, Sun Young ; Park, Jin-hong ; Kim, Jong Hoon ; Park, In Ja ; Lim, Seok-Byung ; Yu, Chang Sik ; Kim, Jin Cheon ; Kim, Tae Won

Purpose : Preoperative chemoradiation (CRT) with capecitabine is a standard treatment strategy in patients with locally advanced rectal cancer (LARC). Temozolomide improves survival of patients with glioblastoma with hypermethylated O6-methylguanine DNA methyltransferase (MGMT). MGMT hypermethylation is one of the colorectal carcinogenesis pathways. We aimed to determine dose-limiting toxicity (DLT) and recommended dose (RD) of temolozomide in combination with capecitabine-based preoperative [...]

A partir des données de deux essais de phase II incluant 269 patients atteints d'un cancer du rectum de stade avancé à haut risque, cette étude analyse les facteurs pronostiques et l'intérêt, en termes d'amélioration de la survie globale, d'une chimiothérapie néoadjuvante suivie d'une chimioradiothérapie

PAN-EX: A pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer

Sclafani, F. ; Brown, G. ; Cunningham, D. ; Wotherspoon, A. ; Tait, D. ; Peckitt, C. ; Evans, J. ; Yu, S. ; Sena Teixeira Mendes, L. ; Tabernero, J. ; Glimelius, B. ; Cervantes, A. ; Thomas, J. ; Begum, R. ; Oates, J. ; Chau, I.

Background : EXPERT and EXPERT-C were prospective phase II clinical trials of neoadjuvant chemotherapy (NACT) followed by chemoradiotherapy (CRT) in high-risk, locally advanced rectal cancer (LARC). Design : We pooled individual patient data from these trials. The primary objective was overall survival (OS) in the intention-to-treat (ITT) population. Prognostic factors were also analysed. Results : 269 patients were included. Of these, 91.1% completed NACT, 88.1% completed CRT and 240 (89.2%) [...]

Cet article passe en revue les études concernant le rôle d'une radiothérapie du cerveau entier dans la prise en charge thérapeutique d'un lymphome primitif du système nerveux central

The role of whole brain radiation in primary CNS lymphoma

Kasenda, Benjamin ; Loeffler, Jay ; Illerhaus, Gerald ; Ferreri, Andrés J.M. ; Rubenstein, James ; Batchelor, Tracy T.

Primary central nervous system lymphoma (PCNSL) is a malignant diffuse large B cell lymphoma confined to the CNS. High-dose methotrexate-based chemotherapy followed by consolidative whole-brain radiotherapy (WBRT) has, historically, been the standard of care. One randomized trial compared consolidative WBRT with observation in patients who achieved complete remission after induction chemotherapy. Although containing methodological flaws, it suggested that WBRT might prolong the duration of [...]

Cet article présente deux méthodes pour mieux décrire l'évolution des effets indésirables associés aux thérapies ciblées dans les essais cliniques

How to report toxicity associated with targeted therapies?

Cabarrou, B. ; Boher, J.M. ; Bogart, E. ; Tresch-Bruneel, E. ; Penel, N. ; Ravaud, A. ; Escudier, B. ; Mahier Ait-Oukhatar, C. ; Delord, J.P. ; Roché, H. ; Filleron, T.

Background In the era of personalized medicine, Molecularly Targeted Therapies (MTT) has modified the outcome of some cancer types. The price of tumour control needs to be balanced with toxicity since these new therapies are administered continuously for several months or sometimes for several years. For cytotoxic drugs, the incidence of adverse event (AE) was traditionally reported as frequency and intensity. This simple measure is not sufficient to capture the recurrent nature and duration of [...]

Basé sur une conférence de consensus organisée en Italie en janvier 2015, cet article passe en revue les données épidémiologiques italiennes concernant le mésothéliome pleural malin, puis présente des recommandations sur la prise en charge de la maladie

The Third Italian Consensus Conference for Malignant Pleural Mesothelioma : State of the art and recommendations

Novello, S. ; Pinto, C. ; Torri, V. ; Porcu, L. ; Di Maio, M. ; Ceresoli, G. ; Magnani, C. ; Silvestri, S. ; Veltri, A. ; Papotti, M. ; Rossi, G. ; Ricardi, U. ; Trodella, L. ; Rea, F. ; Facciolo, F. ; Granieri, A. ; Zagonel, V. ; Scagliotti, G.

Malignant pleural mesothelioma (MPM) remains a relevant public health issue, and asbestos exposure is the most relevant risk factor. The incidence has considerably and constantly increased over the past two decades in the industrialized countries and is expected to peak in 2020-2025. In Italy, a standardized-rate incidence in 2011 among men was 3.5 and 1.25 per 100,000 in men and women, respectively, and wide differences are noted among different geographic areas. The disease remains [...]

Mené aux Etats-Unis auprès de patients atteints d'un cancer du poumon non à petites cellules traité par chimioradiothérapie, cet essai de phase III évalue l'impact, sur la survie globale et la survie sans progression, du volume d'actes médicaux des établissements hospitaliers

Institutional Enrollment and Survival Among NSCLC Patients Receiving Chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617

Eaton, Bree R. ; Pugh, Stephanie L. ; Bradley, Jeffrey D. ; Masters, Greg ; Kavadi, Vivek S. ; Narayan, Samir ; Nedzi, Lucien ; Robinson, Cliff ; Wynn, Raymond B ; Koprowski, Christopher ; Johnson, Douglas W. ; Meng, Joanne ; Curran, Walter J.

Background: The purpose of this analysis is to evaluate the effect of institutional accrual volume on clinical outcomes among patients receiving chemoradiation for locally advanced non–small cell lung cancer (LA-NSCLC) on a phase III trial. Methods: Patients with LA-NSCLC were randomly assigned to 60 Gy or 74 Gy radiotherapy (RT) with concurrent carboplatin/paclitaxel +/- cetuximab on NRG Oncology RTOG 0617. Participating institutions were categorized as low-volume centers (LVCs) or high-volume [...]